KYNTRA BIO, INC. - 8-K Filing
Kyntra Bio reports Q3 2026 revenue of $1.8M and net income of $0.2M while discontinuing FG-3246 development. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $FGEN
Read the full article at SEC EDGAR
Part of the story KYNTRA BIO, INC. - 8-K Filing (3 articles)